Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia

Japanese Journal of Clinical Immunology

Volumn 25, Issue 4, 2002, Pages 337-343

  Kanegane, Hirokazu ^a   Nomura, Keiko ^a   Futatani, Takeshi ^a   Miyawaki, Toshio ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Intravenous immunoglobulin replacement therapy; Trough level; X linked agammaglobulinemia

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOGLOBULIN; MACROLIDE;

AGAMMAGLOBULINEMIA; DRUG COMBINATION; HUMAN; JAPAN; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; X CHROMOSOME LINKED DISORDER;

AGAMMAGLOBULINEMIA; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; GENETIC DISEASES, X-LINKED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; JAPAN; MACROLIDES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33646366150     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.25.337     Document Type: Article

References (25)

1. Ochs, H.D., Smith, C.I.: X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine 10: 399–406, 1996.
2. Sideras, P., Smith, C.I.: Molecular and cellular aspect of X-linked agammaglobulinemia. Adv. Immunol. 59: 135–223, 1995.
3. Tsukada, S., et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72: 279–290, 1993.
4. Vetrie, D., et al.: The gene involved in X-linked agammaglobulinaemia in a member of the src family of protein-tyrosine kinases. Nature 361: 226–233, 1993.
5. Kobayashi, S., et al.: Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan. Hum. Mutat. 97: 424–430, 1996.
6. Hashimoto, S., et al.: Identification of Bruton’s tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: A nationwide study of Btk deficiency in Japan. Blood 88: 561–573, 1996.
7. Futatani, T., et al.: Deficient expression of Bruton’s tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91: 595–602, 1998.
8. Kanegane, H., et al.: Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J. Allergy Clin. Immunol. 108: 1012–1020, 2001.
9. Bruton, O.C.: Agammaglobulinemia. Pediatrics 9: 722–727, 1952.
10. Williams, P.E., et al.: Transmission of nonA or non-B hepatitis by pH 4-treated intravenous immunoglobulin. Vox Sang 57: 15–18, 1989.
11. Bjoro, K., et al.: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N. Engl. J. Med. 331: 1607–1611, 1994.
12. Schiff, R.I.: Transmission of viral infections through intravenous immune globulin. N. Engl. J. Med. 331: 1649–1650, 1994.
13. Yap, P.L., et al.: Hepatitis C virus transmission by intravenous immunoglobulin. J. Hepatol. 21: 455–460, 1994.
14. Centers for Disease Control: Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United Sates Oct 1993-June 1994. MMWR. Morb. Mortal. Wkly. Resp. 43: 505–509, 1994.
15. Abrahamsen, T.G., et al.: Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98: 1127–1131, 1996.
16. Berger, M., et al.: Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann. Intern. Med. 93: 55–56, 1980.
17. Gardulf, A., et al.: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338: 162–166, 1991.
18. Gardulf, A., et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345: 365–369, 1995.
19. Montanaro, A., Pirofsky, B.: Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am. J. Med. 76 (3A): 67–72, 1984.
20. Ochs, H.D., et al.: Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am. J. Med. 76 (3A): 78–82, 1984.
21. Bernatowska, E., et al.: Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin. Immunol. Immunopathol. 43: 153–162, 1987.
22. Roifman, C.M., et al.: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1: 1075–1077, 1987.
23. Liese, J.G., et al.: High-vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am. J. Dis. Child 146: 335–339, 1992.
24. Ejkhout, H.W., et al.: The effect of two different dosage of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randamized, double-blind, multicentric crossover trial. Ann. Intern. Med. 135: 165–174, 2001.
25. Stiehm, E.R.: Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr. Infect. Dis. J. 16: 696–707, 1997.